We’ll start off hearing about an analysis of 9 weeks vs 1 year of adjuvant trastuzumab for patients with early HER2-positive breast cancer. Then, we’ll review a retrospective cohort study that aimed to quantify cancer screening deficits in the United States associated with the COVID-19 pandemic.

Coverage of stories discussed this week on ascopost.com:

Long-Term Analysis of Short-HER Trial Reported: Shorter Duration of Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer

The COVID-19 Pandemic and Cancer Screening Deficits in the United States

To listen to more podcasts from ASCO, visit asco.org/podcasts.